Replies to post #792142 on NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

That is not accurate. UCLA’s dendritic-cell vaccine patents are exclusively licensed to Northwest Biotherapeutics under a worldwide agreement with the Regents of the University of California.

1.  UCLA to NWBO Exclusive License

NWBO’s SEC filings state:

“We hold an exclusive, worldwide license from the University of California covering dendritic-cell-based vaccines invented by Dr. Linda Liau and colleagues. The license provides us rights to develop and commercialize such vaccines for all tumor types.”

(NWBO Form 10-K, March 2024, “Business – Intellectual Property”)

The key patent family, “Optimally Activated Dendritic Cells That Induce an Improved or Increased Anti-Tumor Immune Response” (WO 2017/004230 to US 11,124,768 B2 to EP 4574159 A2 to IL 256522 B2 to CN 107849537 A), lists Dr. Linda Liau and Dr. Robert Prins as inventors, with Northwest Biotherapeutics as the assignee and licensee of record.

The license is exclusive, worldwide, and sublicensable. UCLA retains inventorship, but NWBO holds all commercial rights.

UCLA cannot independently market or license DC-Vax. NWBO controls the commercial pathway globally.

2.  NWBO’s Expanded IP through Roswell Park and the University of Pittsburgh

NWBO’s June 17, 2024 press release announced:

“NW Bio has obtained exclusive worldwide rights to five new patent families from Dr. Pawel Kalinski’s work at Roswell Park covering enhanced dendritic cells, chemokine-modulation regimens, and tumor-microenvironment conditioning designed to boost immune responses and overcome resistance to checkpoint inhibitors.”

This follows NWBO’s 2023 license of Dr. Kalinski’s earlier University of Pittsburgh aDC1 patents, covering IL-12–dominant Type-1 polarized dendritic-cell methods.

Together these portfolios give NWBO control over:

I. The original UCLA DC-Vax blueprint (whole-tumor-lysate loading, maturation, and clinical validation in glioblastoma).

II. The Kalinski IL-12 enhancement layer (aDC1 and CXCR3/CCR5 DC platforms that strengthen potency and trafficking).

3.  Automated Manufacturing IP (Flaskworks EDEN and EDITH)

NWBO owns Flaskworks LLC and its patented EDEN and EDITH systems, which include nine granted U.S. patents and international counterparts extending through 2041. These systems automate dendritic-cell production and digitally verify every manufacturing step, satisfying both MHRA SI 87 and FDA CNPV requirements.

This integration gives NWBO control over the full manufacturing and quality infrastructure behind DC-Vax.

4.  Freedom to Operate Across All Solid TumorsThe UCLA license is not limited to glioblastoma. The SEC filings explicitly state “for all tumor types,” meaning NWBO has legal freedom to expand DC-Vax-L and DC-Vax-Direct into any solid-tumor indication, including ovarian, lung, and pancreatic cancers.

No other entity can commercialize the same technology without NWBO’s consent or sublicense.

Conclusion

The suggestion that UCLA retains independent ownership of the DC-Vax technology is incorrect. UCLA is the originating research institution, while NWBO holds the exclusive global commercial rights. NWBO has further consolidated the field by licensing complementary intellectual property from the University of Pittsburgh and Roswell Park and by acquiring Flaskworks’ automated manufacturing patents. The company now holds complete freedom to operate in dendritic-cell vaccine development across all solid-tumor indications.